Faculty Bibliography

Aortoiliac occlusive disease is a significant cause of lower extremity ischemic symptoms. Over the past two decades, most patients have been treated with a variety of surgical procedures, including aortofemoral and extra-anatomic bypasses. Most recently, percutaneous balloon angioplasty and stents have been successfully used for the treatment of limited iliac lesions. New endovascular grafts that combine vascular grafts with stents in a device with new characteristics may allow the successful treatment of patients with extensive aortoiliac occlusive disease in a less invasive fashion. In our early experience, the endovascular grafts were constructed with Palmaz balloon-expandable stents and standard polytetrafluoroethylene (PTFE) grafts. The 18-month primary and secondary patency rates were 89% and 100%, respectively, with a limb salvage rate of 94%. Endovascular grafts can be successfully used to treat patients with extensive aortoiliac occlusive disease, with excellent early results. Long-term results and further graft improvements will define their role in the treatment of patients with aortoiliac occlusive disease

PURPOSE: Although axillobifemoral bypass procedures have a lower mortality rate than aortobifemoral bypass procedures, they are limited by decreased patency, moderate hemodynamic improvement, and the need for general anesthesia. This report describes an alternative approach to bilateral aortoiliac occlusive disease using unilateral endovascular aortofemoral bypass procedures in combination with standard femorofemoral reconstructions. METHODS: Seven patients who had bilateral critical ischemia and tissue necrosis in association with severe comorbid medical illnesses underwent implantation of unilateral aortofemoral endovascular grafts, which were inserted into predilated, recanalized iliac arteries. The proximal end of the endovascular graft was fixed to the distal aorta or common iliac artery with a Palmaz stent. The distal end of the graft was suture-anastomosed to the ipsilateral patent outflow vessel, and a femorofemoral bypass procedure was then performed. RESULTS: All endovascular grafts were successfully inserted through five occluded and two diffusely stenotic iliac arteries under either local (1), epidural (5), or general anesthesia (1). The mean thigh pulse volume recording amplitudes increased from 9 +/- 3 mm to 30 +/- 7 mm and from 6 +/- 2 mm to 26 +/- 4 mm ipsilateral and contralateral to the aortofemoral graft insertion, respectively. In all cases the symptoms completely resolved. Procedural complications were limited to one local wound hematoma. No graft thromboses occurred during follow-up to 28 months (mean, 17 months). CONCLUSIONS: Endovascular iliac grafts in combination with standard femorofemoral bypass grafts may be an effective alternative to axillobifemoral bypass in high-risk patients who have diffuse aortoiliac occlusive disease, particularly when bilateral axillary-subclavian disease is present

The field of vascular surgery is facing an important crossroads. Increasingly, less invasive alternatives are becoming available for the treatment of vascular lesions previously amenable only to conventional operative repair. Endovascular devices and techniques have been developed in experimental and clinical settings in an attempt to reduce the morbidity and mortality seen with conventional treatments and provide for long-term function at reduced costs. One such device is the transluminally placed endovascular graft which has been used at the Montefiore Medical Center in New York to treat patients with a wide variety of vascular pathologies, including abdominal and peripheral aneurysms, aortoiliac and infrainguinal atherosclerotic occlusive lesions, and lesions of traumatic or iatrogenic origin. This work represents our initial results with the endoluminally deployed stented graft in 92 patients with 102 arterial lesions treated over a 30-month period.

Stroke is the third leading cause of death in the United States and a major source of morbidity. [1] Recent studies have shown a potential use for thrombolytic agents in the treatment of ischemic stroke (IS) but these agents are contraindicated in intracerebral hemorrhage (ICH). A computed tomographic scan is used to distinguish between these two stroke types prior to the use of thrombolytic agents, but may not be readily obtainable. Decision making aids such as algorithms developed at Guy's Hospital and Strong Memorial Hospital have been designed in an attempt to make this distinction on clinical grounds. We have constructed computerized medical decision-making (CMD) systems based upon these algorithms and compared their performance to a system we developed with the use of National Stroke Data Bank data. Relevant medical data for each of 337 patient cases in the Mount Sinai Hospital Stroke Data Bank were presented to each of the CMD systems. In consideration of the clinical task of using thrombolytic agents, we attempted to maximize the positive predictive value (PPV) for ischemic stroke. The CMD systems based upon the Guy's Hospital and Mount Sinai algorithms produced PPV's of 95% and 94% with sensitivities of 77% and 78% respectively compared to a PPV of 93% and sensitivity of 56% with the Strong Memorial CMD system. The Mount Sinai CMD system was judged more efficacious than the Guy's Hospital system in that it required less clinical information that could be more easily obtained to arrive at similar results.